Isorhamnetin inhibits cholangiocarcinoma proliferation and metastasis via PI3K/AKT signaling pathway
Our study demonstrated for the first time that isorhamnetin can inhibit the progression of CCA through PI3K/AKT, and that AKT1 may be a target of isorhamnetin for the treatment of CCA.
Authors
- Min Hou
- Jia Zhou (ORCID: https://orcid.org/0000-0002-2811-1090)
- Yu Chen (ORCID: https://orcid.org/0000-0002-8206-3325)
- Jie Liu (ORCID: https://orcid.org/0000-0002-1129-9584)
- Xu Chen (ORCID: https://orcid.org/0000-0002-6463-9933)
- Yufang Leng (ORCID: https://orcid.org/0000-0002-1840-9176)
- Zhiguo Tan
Institutions
- Lanzhou University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-04-05
- DOI
- https://doi.org/10.1007/s12672-025-02217-8
- Citations
- 1
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.94